The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of biweekly CPT-11 plus CDDP for patients with unresectable or recurrent gastric cancer refractory to S-1.
Y. Rino
No relevant relationships to disclose
T. Oshima
No relevant relationships to disclose
N. Yukawa
No relevant relationships to disclose
R. Yamada
No relevant relationships to disclose
T. Sato
No relevant relationships to disclose
M. Takahashi
No relevant relationships to disclose
H. Matsukawa
No relevant relationships to disclose
Y. Yamamoto
No relevant relationships to disclose
R. Shiraishi
No relevant relationships to disclose
M. Masuda
No relevant relationships to disclose
T. Imada
No relevant relationships to disclose